Should You Watch Out For The Allchem Lifescience IPO?
Between CY 2019 and CY 2023, the global active pharmaceutical ingredients (API) intermediates grew at a CAGR of 5%. The industry is anticipating a CAGR growth of 7% between CY 2024 and CY 2029. As countries like India and China emerge as cost-effective regions for intermediates production, Allchem Lifescience Private Limited is gearing up for the Allchem Lifescience IPO.
While Emkay Global Financial Services Limited is managing the Allchem Lifescience Private Limited IPO, MUFG Intime India Private Limited is registering it. Don’t miss out on the Allchem Lifescience share allotment status.
To know more about the Allchem Lifescience share price, turnover and other key details, check out the Allchem Lifescience Limited DRHP.
Note: 50% shares will be unlocked 30 days after allotment, while the rest will be free from lock-in restrictions after 90 days.
Discussed in this section are the key takeaways about the Allchem Lifescience Private Limited IPO, including the Allchem Lifescience IPO price, issue size, timeline, and other key details.
Allchem Lifescience Private Limited filed its DRHP with the SEBI and the exchange on 18 March 2025. The approval was received on 21 August 2025. The Allchem Lifescience DRHP did not provide the IPO opening and closing dates. Therefore, stay tuned for updates.
Strengths and Risks of Allchem Lifescience IPO
Discussed below are the key strengths and risks associated with Allchem Lifescience, as disclosed by the Allchem Lifescience Limited DRHP.
Strengths
Long-Standing Client Relationships: The company has client relationships spanning several years. The minimum and maximum tenures the top three clients spent with the company are 8 and 11 years, respectively, in 2024.
Diverse Customer Base: The company operates in 13 Indian states and 22 foreign countries, enjoying a diverse customer base as of 2024.
Manufacturing Facility: With a capacity of 1,133.50 KL as of 31 December 2024, the company has a strong manufacturing facility, with a focus on sustainability.
Innovation: The company also maintains its focus on the development of new chemistries that can have a range of industry applications.
Risks
Dependence on the Pharmaceutical Industry: Like other fiscal years, a significant portion (90.85%) of revenue in 2024 came from the pharma sector, resulting in a dependence on pharma industry performance.
Customer Dependence: A significant portion of the revenue was derived from top clients, resulting in a significant dependence on such relations.
Geographic Concentration: In both domestic and international segments, the business has few key locations where the revenue is most concentrated.
Reliance on Vendors: The cost of raw materials is a significant proportion of the expenses. Moreover, the supply is concentrated among the top suppliers.
As of 22 October 2025, the Allchem Lifescience IPO GMP is not available. Moreover, GMP changes often. Check the latest GMP here. However, for a complete breakdown of the Allchem Lifescience IPO, don’t miss out on the offer documents and the detailed FinnPick IPO analysis.
Don’t forget to check out the live subscription status before you hit the Apply now.
1. What is the Allchem Lifescience IPO GMP?
As of 22 October 2025, the Allchem Lifescience IPO GMP is unavailable. However, it may change soon. For the latest sentiment, you can look for the GMP updates.
2. What is the Allchem Lifescience IPO date?
The open and closing Allchem Lifescience IPO dates are unavailable as of 22 October 2025. However, investors can monitor live subscription details in real time.
3. What is the Allchem Lifescience IPO size and price?
The Allchem Lifescience DRHP does not disclose the overall issue size. Moreover, the final issue price is also unavailable as of 22 October 2025. Don't forget to check the allotment details.
4. Do I need a demat account to bid for the Allchem Lifescience IPO?
Yes, a demat account is required to bid for the Allchem Lifescience IPO. Click here to get the ultimate list of the top demat account providers.
